Metformin hydrochloride pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Metformin Hydrochloride Pharmacokinetics: Absorption, Distribution, and Elimination
Absorption and Bioavailability of Metformin Hydrochloride
Metformin hydrochloride is slowly absorbed from the small intestine, with incomplete gastrointestinal absorption and significant variability in absolute bioavailability across species—ranging from as low as 4% in equids to about 60% in humans 910. In humans, the usual effective oral dose is 1.5–2.5 g/day, divided into two or three doses . The absorption rate and extent can be influenced by food intake; high-fat, high-calorie meals lower both the rate and extent of absorption, resulting in a delayed time to reach maximum plasma concentration (Tmax) and reduced maximum concentration (Cmax) and area under the curve (AUC) by approximately 30–40% 25. This suggests that higher doses may be needed to maintain therapeutic effects when metformin is taken with such meals 25.
Pharmacokinetic Variability: Species, Disease State, and Environmental Factors
Pharmacokinetic parameters of metformin hydrochloride can differ significantly between species and under different physiological or pathological conditions. For example, in diabetic rats, metformin shows a much higher Cmax and a dramatically prolonged half-life (t1/2) compared to normal rats, with a corresponding decrease in clearance (Cl/F), indicating slower elimination in the diabetic state . Allometric scaling across nine species shows that systemic clearance of metformin correlates with body weight, and tissue distribution is highly variable, likely due to differences in transporter expression . In addition, exposure to high-altitude hypoxia in rats increases the half-life of metformin, possibly due to reduced expression of transporters involved in drug elimination, although AUC and clearance may not change significantly .
Distribution and Elimination
Metformin is not metabolized by the liver and is primarily eliminated unchanged by the kidneys . Its half-life in humans is about five hours, but this can vary in other species and under different conditions 910. The volume of distribution is broad, ranging from 0.32 to 10.1 L/kg across species, with muscle tissue being a major site of distribution . Renal clearance is a key determinant of metformin elimination, and the drug is contraindicated in patients with impaired renal function due to the risk of accumulation and lactic acidosis .
Formulation Effects: Immediate, Extended, and Gastric-Retentive Release
Different formulations of metformin hydrochloride can alter its pharmacokinetic profile. Gastric-retentive, extended-release tablets provide a slower, more prolonged release of metformin, resulting in lower Cmax, longer Tmax, and increased bioavailability compared to immediate-release formulations . Sustained-release microparticle formulations in animal studies also show delayed Tmax, decreased Cmax, and prolonged half-life, but may reduce overall bioavailability compared to oral solutions .
Bioequivalence and Combination Products
Studies in healthy volunteers show that different brands and formulations of metformin hydrochloride, including fixed-dose combinations with other antidiabetic agents, are generally bioequivalent under both fasting and fed conditions, provided they meet regulatory criteria 358. This means that switching between equivalent products is unlikely to significantly affect clinical outcomes in most patients.
Conclusion
Metformin hydrochloride’s pharmacokinetics are influenced by food intake, disease state, species differences, environmental factors, and formulation type. It is slowly absorbed, widely distributed, and primarily eliminated by the kidneys. Food, especially high-fat meals, can reduce and delay absorption, while disease states like diabetes and environmental factors such as hypoxia can alter its elimination. Extended-release and gastric-retentive formulations can provide more stable plasma concentrations. Understanding these factors is important for optimizing metformin therapy and ensuring safe and effective use across different patient populations.
Sources and full results
Most relevant research papers on this topic
Comparison on the Pharmacokinetic of Metformin Hydrochloride between Normal and Diabetic Rats
Metformin hydrochloride has significant differences in pharmacokinetic parameters between normal and diabetic rats.
Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies
A high-fat, high-calorie diet reduces metformin absorption, suggesting increased dosage is needed to maintain the same treatment effect.
Pharmacokinetics of Metformin Gastric‐Retentive Tablets in Healthy Volunteers
Gastric-retentive extended-release metformin tablets show extended-release plasma concentration profiles and increased bioavailability compared to immediate-release tablets in healthy volunteers.
Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species
Metformin absorption and renal clearance are highly correlated with body weight, but tissue distribution varies significantly due to transporter differences.
Metformin hydrochloride: an antihyperglycemic agent.
Metformin hydrochloride effectively lowers blood glucose levels without causing hypoglycemia, making it an effective alternative to sulfonylureas for obese and non-obese patients with non-insulin-dependent diabetes mellitus.
DOI